StockData
Geron Corp logo

Geron Corp (GERN) stock

GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 2/30
$1.00+0.06 (+6.17%)

Close on Nov 17, 2026Market cap $642.47MP/E –Yield –

Geron r&d expenses

Research and development expenses are spending on new products and technology.

Geron's R&D Expenses for the twelve months ending Jun 30, 2026 was $71.61M, down 10.9% year over year. For fiscal 2025 it was $71.43M, down 31.1% from the year before. Over ten years it grew 14.9% a year on average. The highest annual figure on record is $125.05M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$71.43M-31.1%
FY2024Dec 31, 2024$103.74M-17.0%
FY2023Dec 31, 2023$125.05M+30.9%
FY2022Dec 31, 2022$95.52M+11.4%
FY2021Dec 31, 2021$85.73M+66.5%
FY2020Dec 31, 2020$51.49M-1.1%
FY2019Dec 31, 2019$52.07M+287.7%
FY2018Dec 31, 2018$13.43M+21.7%
FY2017Dec 31, 2017$11.03M-38.9%
FY2016Dec 31, 2016$18.05M+1.2%
FY2015Dec 31, 2015$17.83M-13.9%
FY2014Dec 31, 2014$20.71M-10.6%
FY2013Dec 31, 2013$23.16M-54.9%
FY2012Dec 31, 2012$51.37M-25.9%
FY2011Dec 31, 2011$69.32M+12.4%
FY2010Dec 31, 2010$61.69M+7.1%
FY2009Dec 31, 2009$57.62M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.03M+1.4%
Q1 FY2026Mar 31, 2026$14.96M-0.8%
Q4 FY2025Dec 31, 2025$13.55M-42.2%
Q3 FY2025Sep 30, 2025$21.07M+4.6%
Q2 FY2025Jun 30, 2025$21.74M-29.4%
Q1 FY2025Mar 31, 2025$15.08M-48.7%
Q4 FY2024Dec 31, 2024$23.43M-28.8%
Q3 FY2024Sep 30, 2024$20.15M-31.5%
Q2 FY2024Jun 30, 2024$30.78M-13.3%
Q1 FY2024Mar 31, 2024$29.37M+7.9%
Q4 FY2023Dec 31, 2023$32.91M+16.7%
Q3 FY2023Sep 30, 2023$29.43M+19.6%
Q2 FY2023Jun 30, 2023$35.49M+72.2%
Q1 FY2023Mar 31, 2023$27.22M+23.2%
Q4 FY2022Dec 31, 2022$28.21M+16.8%
Q3 FY2022Sep 30, 2022$24.60M+32.8%
Q2 FY2022Jun 30, 2022$20.61M-6.1%
Q1 FY2022Mar 31, 2022$22.10M+4.7%
Q4 FY2021Dec 31, 2021$24.15M+48.8%
Q3 FY2021Sep 30, 2021$18.53M+36.1%
Q2 FY2021Jun 30, 2021$21.94M+102.3%
Q1 FY2021Mar 31, 2021$21.11M+95.5%
Q4 FY2020Dec 31, 2020$16.23M-34.9%
Q3 FY2020Sep 30, 2020$13.61M+22.5%
Q2 FY2020Jun 30, 2020$10.85M+7.0%
Q1 FY2020Mar 31, 2020$10.80M+82.9%
Q4 FY2019Dec 31, 2019$24.92M+390.5%
Q3 FY2019Sep 30, 2019$11.11M+310.4%
Q2 FY2019Jun 30, 2019$10.13M+216.3%
Q1 FY2019Mar 31, 2019$5.91M+142.0%
Q4 FY2018Dec 31, 2018$5.08M+101.4%
Q3 FY2018Sep 30, 2018$2.71M+2.7%
Q2 FY2018Jun 30, 2018$3.20M+28.2%
Q1 FY2018Mar 31, 2018$2.44M-27.7%
Q4 FY2017Dec 31, 2017$2.52M-38.8%
Q3 FY2017Sep 30, 2017$2.64M-38.9%
Q2 FY2017Jun 30, 2017$2.50M–
Q1 FY2017Mar 31, 2017$3.37M–
Q4 FY2016Dec 31, 2016$4.12M–
Q3 FY2016Sep 30, 2016$4.32M–

More Geron figures

See a number that looks wrong?